Metastatic castration resistant prostate cancer: Updates from ASCO 2019

Bookmark and Share
Published: 7 Jun 2019
Views: 2763
Dr Neal Shore, Dr Joaquin Mateo and Prof Karim Fizazi

Dr Neal Shore (Carolina Urologic Research Center, South Carolina, USA), Dr Joaquin Mateo (Vall d'Hebron Institute of Oncology, Barcelona, Spain) and Dr Karim Fizazi (Institut Gustave Roussy, Paris, France) discuss the treatment and management of metastatic castration resistant prostate cancer (mCRPC). 

Dr Shore provides and overview of the current treatment landscape for mCRPC before Dr Mateo summarises the TOPARP-A study and results of the TOPARP-B study presented at ASCO 2019. The panel then go on to discuss ongoing trials including PROFOUND and TRITON3 as well as summarising the ARAMIS and VISION studies.

The session concludes with Dr Mateo offering advice on how to manage patients on PARP inhibitors and the associated adverse event profile of this class of drugs.

Current clinical landscape of mCRPC
Summary of the TOPARP-A study and the latest results from the TOPARP-B study
Role of PARP inhibitors in mCRPC from the PROFOUND and TRITON3 trials
Key findings of the ARAMIS trial
Prostate-specific membrane antigen (PSMA) as a therapeutic target
Overview of the VISION trial
Use of bi-specific T-cell engagers (BiTEs) as a treatment option
Adverse events associated with PARP inhibitors
Genetic testing to identify germline and somatic mutations

This programme has been supported by an unrestricted educational grant from AstraZeneca.